# Thymosin Alpha-1: Research Overview — Peptide Care Now > A literature summary of thymosin alpha-1 (thymalfasin), the immunomodulatory peptide approved in 35+ countries: TLR signaling, T-cell restoration, sepsis RCT data, COVID-19 evidence, and cancer adjuvant research. A 28-amino-acid immunomodulatory peptide with four decades of clinical data — approved in over 35 countries, studied in sepsis, COVID-19 and cancer, with a 2025 Phase 3 null result that reframes expectation. ## The short version Thymosin alpha-1 is a 28-amino-acid peptide derived from the natural precursor prothymosin alpha. Its synthetic form, thymalfasin, is an approved prescription drug in more than 35 countries — used primarily for chronic viral hepatitis and immune reconstitution — but it does not hold FDA marketing approval in the United States [9]. The molecule's core job is at the innate-adaptive immune interface: it activates dendritic cells through Toll-like receptors, promotes T-cell maturation, and can either boost effector immunity (in immunosuppressed patients) or dampen hyperinflammation (via the IDO/tryptophan pathway), giving it a dual regulatory profile [9]. What makes thymosin alpha-1 uniquely honest as a research subject is that it has been tested in large randomized controlled trials — including a 2025 Phase 3 double-blind trial of 1,106 sepsis patients that returned a null mortality result (hazard ratio 0.99) [8]. That trial outcome is a direct caution against assuming benefit outside the settings where evidence is strongest. This page reports the full picture: the positive signals, the null trial, and what each means for how to read the literature. ## What it is Thymosin alpha-1 is a 28-amino-acid N-terminally acetylated polypeptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. It is highly acidic (no aromatic residues, no disulfide bonds), and N-terminal acetylation is essential for its biological activity — the unmodified peptide is less potent. In the body, it is cleaved from the 113-amino-acid precursor prothymosin alpha and is found in the thymus and peripheral blood [9]. The synthetic drug thymalfasin is sequence-identical to the natural peptide. It should be carefully distinguished from several other thymic peptides: thymulin is a different, shorter zinc-dependent nonapeptide hormone (see the [thymulin page](/thymulin)); thymosin beta-4 / TB-500 is an entirely different protein with an actin-binding function; thymalin is a bovine thymic glandular extract with no structural identity to thymosin alpha-1; thymopentin is yet another short synthetic peptide. Consumer sources conflate these routinely. ## How it works Thymosin alpha-1 operates at the interface between innate and adaptive immunity. Its primary signal route involves Toll-like receptors — specifically TLR2 and TLR9 — on dendritic cells and monocytes. Engagement of these receptors by thymosin alpha-1 drives dendritic-cell maturation, upregulates MHC class II antigen presentation and HLA-DR expression, promotes IL-12 production, and thereby activates T-cell differentiation and Th1 polarization [9][11]. In parallel, thymosin alpha-1 can engage the indoleamine 2,3-dioxygenase (IDO) and tryptophan catabolism pathway to generate immunoregulatory T cells (Tregs). This bidirectional capacity — immune stimulation in deficiency states, immune tempering in hyperactivation — is why its clinical literature spans immunosuppressed patients (viral hepatitis, cancer chemotherapy recipients) and critically ill hyperinflammatory patients (sepsis, COVID-19) [9][10]. A well-documented mechanism relevant to severe COVID-19 is reversal of T-cell exhaustion. Exhausted CD8+ T cells overexpress checkpoint molecules PD-1 and Tim-3, reducing their cytotoxic effectiveness; thymosin alpha-1 reduced PD-1 and Tim-3 expression and increased total T-cell counts in patients with severe lymphocytopenia, correlating with improved survival in a retrospective cohort [10]. ## What the research shows *Four decades of clinical literature — the comprehensive review.* A 2020 review spanning the entire clinical literature describes standard subcutaneous dosing ranges from 0.8 to 6.4 mg (single dose) and 1.6 to 16 mg for multiple-dose regimens, documents approval in more than 35 countries, and characterizes the safety profile as generally benign — the dominant adverse events being mild, transient, local injection-site reactions [9]. *Sepsis: a positive signal.* The multicentre ETASS randomized controlled trial (361 adult ICU patients with severe sepsis) found 28-day all-cause mortality of 26.0% in the thymosin alpha-1 group versus 35.0% in controls — an absolute reduction of approximately 9 percentage points that was marginally significant (log-rank P=0.049). Monocyte HLA-DR expression also improved in the treatment arm [12]. *Sepsis: the 2025 null result.* The Phase 3 TESTS trial (1,106 adults across 22 centers, double-blind, placebo-controlled) found no statistically significant difference in 28-day all-cause mortality: 23.4% in the thymosin alpha-1 arm versus 24.1% in placebo, hazard ratio 0.99 (95% CI 0.77–1.27), P=0.93 [8]. This null result is the most rigorous sepsis data available, and directly tempers interpretation of smaller positive trials. *Severe COVID-19.* A retrospective review of 76 patients with severe COVID-19 found thymosin alpha-1 treatment associated with significantly reduced mortality (11.11% vs 30.00%, P=0.044), alongside increased blood T-cell numbers and reduced PD-1 and Tim-3 expression on CD8+ T cells, reversing T-cell exhaustion — an effect most pronounced in elderly patients [10]. *Cancer immunoadjuvant.* A 2019 oncology reappraisal positioned thymosin alpha-1 as a combination immunostimulant in melanoma, hepatocellular carcinoma, and lung cancer, describing a mechanism that may help convert immunologically "cold" tumors to "hot" (T-cell infiltrated) while also restoring mucosal homeostasis to mitigate checkpoint-inhibitor toxicity [11]. ## Reported effects, cautions & safety Thymosin alpha-1 has a substantially larger real-world dataset than most research peptides on account of its international approval and post-marketing surveillance across hundreds of thousands of patients. That history shapes what is known about its safety and what users report. *Anecdotal reports (not clinical data)* from peptide research communities and clinician commentary describe: - **Fewer or shorter colds and seasonal infections** as the most commonly reported benefit — self-reported impression, not measured immune function. - **Faster recovery from a run-down period or illness**, reported as bouncing back sooner during a course, without a controlled outcome being tracked. - **Injection-site redness, itching or stinging** as the single most common complaint — mild, transient, and consistent with the documented safety profile [9]. - **Occasional short-lived flu-like feeling** reported early in a course by a minority of users, described as self-limited. - **"Didn't notice anything"** — a common report for an immunomodulator whose effects are biochemical rather than perceptible, and unsurprising given that the peptide's mechanism does not produce immediately felt changes. - **Tempered expectations after the null sepsis headline** — more informed community members note the 2025 Phase 3 TESTS result and caution against assuming dramatic benefits outside the strongest evidence settings. *Cited safety cautions from the literature:* - **Theoretical caution in autoimmune disease.** Thymosin alpha-1 is an immunostimulant that promotes dendritic-cell maturation and Th1 polarization; in established autoimmunity, broadly enhancing effector immunity carries a theoretical concern — though the peptide also has counterbalancing regulatory-T-cell activity, and circulating levels are actually reduced in several autoimmune diseases [9]. - **Theoretical caution in transplant recipients.** Deliberate immunosuppression is the cornerstone of solid-organ transplant management; a peptide that restores T-cell maturation and reverses T-cell exhaustion could in principle work against intentional immunosuppression [9]. - **Limited pregnancy and lactation data.** Decades of human data come from hepatitis, sepsis, cancer, and immune-reconstitution populations; dedicated studies in pregnancy and lactation are absent, so fetal or infant risk cannot be characterized [9]. - **Null Phase 3 sepsis data.** The largest, most rigorous sepsis trial returned a null result (HR 0.99, P=0.93) [8]; benefit should not be assumed, especially outside chronic viral hepatitis where the signal is strongest. - **US non-approval and research-grade quality risk.** Not FDA-approved for marketing in the US; material obtained as research-grade peptide is outside the regulated drug-quality chain, so purity, actual content, sterility, and identity are not guaranteed [9]. ![Thymosin Alpha-1 dendritic cell activation and T-cell maturation pathway in cold indigo night palette](/images/thymosin-alpha-1.webp) ## Where it fits in immune research Thymosin alpha-1 is the more clinically documented compound on this desk. With approval in more than 35 countries, multiple RCTs, a Phase 3 trial, and a 2025 null result that the literature must now reckon with, it represents a case study in what rigorous testing looks like for an immunomodulatory peptide [8][9]. Its story is useful not just for the positive signals — COVID-19 T-cell restoration, cancer combination data — but for what the null sepsis result reveals about the limits of extrapolating smaller, less rigorous trials. Where [thymulin](/thymulin) is the narrow hormonal signal from the thymus itself — a zinc-dependent nonapeptide operating in a tightly defined neuroendocrine axis — thymosin alpha-1 is the broader immunostimulatory peptide whose effects span the innate-adaptive interface. They are not the same molecule, not interchangeable, and not additive in any sense established by current evidence. See the [comparison page](/compare) for a structured side-by-side. --- A data-forward reading desk for thymic immunology research — effect sizes and study designs, not prescriptions.